comparemela.com

Latest Breaking News On - 2024 transplantation amp cellular therapy meetings - Page 1 : comparemela.com

Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers

Encouraging data with RFS, OS, and NRM for Orca-T was also matched in a population of patients with hematologic cancers aged 55 years and older.

Novartis pharmaceuticals corporationBone marrow transplantation stem cell processing centerAstrazeneca pharmaceuticalsPfizer incSeagen incJonsson comprehensive cancer centerJazz pharmaceuticalsArog pharmaceuticalsUniversity of california los angelesCellular therapyCalifornia los angelesComprehensive cancer centerOrca bioPhase 1b trial nct040136852024 transplantation amp cellular therapy meetingsPatients with hematologic cancers aged 55 years and older

Immune Engager Therapies Demonstrate Promise Following Relapse on Ide-Cel in Multiple Myeloma

Treatment with immune engager therapies following relapse on ide-cel resulted in better median PFS vs other therapies for patients with multiple myeloma.

Murali janakiramCellular therapy meetings2024 transplantation amp cellular therapy meetingsImmune engager therapiesProgression free survivalMultiple myelomaIdecabtagene vicleucelIde cel

Concomitant Azoles Does Not Affect Clinical Outcomes With Ruxolitinib in Acute GVHD

Concomitant azoles did not negatively affect efficacy with ruxolitinib or best available therapy in patients with acute graft-versus-host disease.

San antonioUnited statesZahra mahmoudjafairUniversity of kansas medical centerTrial groupCellular therapyKansas medical centerConcomitant azolesRuxolitinib treatmentAcute graft versus host diseasePost hoc analysisRandomized phaseCellular therapy meetingsTransfus cell2024 transplantation amp cellular therapy meetingsPhase 3 reach2 study nct02913261

vimarsana © 2020. All Rights Reserved.